4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
MBX Biosciences, Inc. (MBX) operates in the Biotechnology industry and is headquartered in Carmel, United States with about 63 employees. Its market capitalization is roughly $3 billion. In the fiscal year ended 2025-12-31, MBX reported $0M in revenue and ($87M) in net income.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($98M) | ($68M) | ($35M) | ($25M) |
| Net Income | ($87M) | ($62M) | ($33M) | ($26M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($27M) | ($26M) | ($24M) | ($22M) | ($26M) |
| Net Income | ($24M) | ($22M) | ($22M) | ($19M) | ($24M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Assets | $385M | $268M | $84M | $45M |
| Total Liabilities | $16M | $11M | $157M | $88M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MBX viewer.
About TickerBase · Data methodology & sources